Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor, or factor Xa inhibitors in patients with stable coronary, cerebrovascular, or peripheral arterial disease without clear indication for anticoagulant therapy (no added benefit from dual therapy). This evidence concerns the gene F10 and peripheral arterial disease.